While bacterial-derived asparaginase has been approved to treat acute lymphoblastic leukemia and non-Hodgkin lymphoma, the therapeutic efficacies of other amino acids- depleting enzymes in multiple types of cancers are still under clinical investigation (9, 161). This evidence concerns the gene ASPG and acute lymphoblastic leukemia.